Jiuzhou Pharmaceutical announced that its holding subsidiary Zhejiang Jiuzhou Biopharmaceutical Co., Ltd. received the "Drug Registration Certificate" for Sildenafil Citrate Orodisintegrating Tablets approved and issued by the State Drug Administration. The drug is an iterative dosage form of sildenafil developed by Pfizer based on a patient-centered approach and was approved for import in China in 2019. At present, the manufacturers that have obtained the drug registration certificate in China are mainly Sichuan Kelun Pharmaceutical and Guangdong Taienkang Pharmaceutical. In 2023, the total sales of sildenafil citrate tablets in the domestic medical market and retail market will be 5.217 billion yuan. Jiuzhou Pharmaceutical has invested approximately 13.52 million yuan in the research and development of sildenafil citrate orodisintegrating tablets.